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Abstract 
The investigation deals with the affection of permeation of mupirocin from the Bactroban® Leciva 
ointment through full-thickness pig ear skin by alaptide that was applied in micronized or nanonized form 
as a potential excipient. Alaptide, (S)-8-methyl-6,9-diazaspiro[4.5]decan-7,10-dione, was the original 
Czech compound. It was discovered that micronized alaptide significantly enhanced the permeation of 
mupirocin within 1 h after administration (approx. 5-fold). On the other hand, nanonized alaptide almost 
completely inhibited permeation of mupirocin from Bactroban® Leciva through the skin. Rapid primary 
screening showed that the two forms of alaptide differently influenced the depth and the rate of 
permeation/penetration of mupirocin into/through the skin, i.e., affect curative effect of mupirocin on/in 
skin immediately after application of drug formulation. 
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Introduction 
Development in the field of pharmaceutical dosage forms results in the discovery of additional highly 
sophisticated drug delivery systems that allow for the maintaining of constant levels of active substances in 
organisms. Transdermal administration of drugs represents an alternative to conventional pharmaceutical 
dosage forms. However, transdermal drug delivery often faces the problem of insufficient or no 
penetration of active pharmaceutical substances through the skin, because skin itself is a physiological 
barrier that protects the body from toxins and microorganisms from the external environment. To solve 
this critical issue, various approaches to overcoming the skin barrier have been developed. These 
approaches can be classified as chemical (modification of drugs using transdermal chemical penetration 
enhancers) or physical (modification of drug particle size to nanosize) enhancement techniques [1−5 and 
refs. therein]. 
In general, transport mechanisms support nanomaterial penetration [6−9]; however, the promise of 
nanoparticle-mediated drug delivery into the epidermis and dermis without barrier modification has met 
with little success. The penetration of particulate materials into the skin is a very complex issue. Therefore, 
the interaction of nanoparticles with the skin and especially skin models is an intriguing field of research. 
However, the data obtained do not show a clear image of the effect of nano-carriers. In particular, the 
ADMET & DMPK 2(1) (2014) 56-62 Mupirocin permeation 
doi: 10.5599/admet.2.1.26 57 
penetration of such particles is an open and controversially discussed issue. The literature reports different 
results primarily on pig or murine skin, showing either strong penetration (pig and mouse) or the opposite. 
Looking only at the sizes of the particles, no conclusive picture can be obtained. The fact that nanoparticles 
did not penetrate/permeate or expressed decreased penetration/permeation was described and discussed 
in a number of recent papers [10−15]. 
Our team focused on investigating a slightly different topic, namely the influence of a transdermal 
chemical penetration enhancer (CPE) in micronized and/or nanonized form on the modification of the 
permeation/penetration properties of a drug through the skin. In this investigation alaptide was chosen as 
a potential CPE and mupirocin was selected as a tested drug. Alaptide (chemically, (S)-8-methyl-6,9-
diazaspiro[4.5]decan-7,10-dione, see Fig. 1) is an original Czech compound that was prepared by Kasafirek 
et al. in the 1980s [16,17]. During biological assays, it was found that alaptide affected the behaviour and 
learning abilities of rodents, particularly rats and mice; as such, it can be classified as nootropic [18−20].  
Alaptide also expressed anti-proliferative activity [21] and immunomodulatory effect [22]. 
Additionally, alaptide reduced the number and the extent of experimental gastric ulcers. The gastric juice 
quantity, acidity and enzymatic activity were not influenced [23,24]. Alaptide was tested on the diploid cell 
line of a human embryonic lung LEP-19, where it expressed a stimulating effect on the growth and breeding 
of cells without transformation changes in their morphology. In vitro tests also showed that alaptide 
increased cell proliferation; both the above mentioned effects can significantly contribute to the curative 
effect of alaptide.  
An influence of alaptide on epidermal regeneration was investigated in a number of tests. In vivo 
experiments were performed using domestic pigs to which alaptide was applied on experimental injury; 
faster skin regeneration was observed after alaptide application. Similarly, alaptide accelerated curing of 
experimental skin injuries in rats [17,25]. As alaptide was designed as an analogue of melanocyte-
stimulating hormone release-inhibiting factor (MIF-1), it negatively affects the inhibition of the release of 
melanocyte-stimulating hormone and thus increases the concentration of melanocytes in the epidermis.  
Melanocytes significantly influence the creation and function of keratinocytes by means of 
melanosomes [26−28]. Metabolic studies in rats showed that alaptide is readily absorbed from the 
gastrointestinal tract and penetrates the blood-brain barrier [17,21]. It is excreted unchanged, mostly via 
urine (90%); a similar metabolic profile was also found in humans [29]. Any toxicity (acute, subchronic and 
chronic) as well as genotoxic, teratogenic and embryotoxic effects of alaptide were not observed 
[17,21,30]. Additionally, it was found that both alaptide enantiomers did not induce the biotransformation 
enzymes (1A1, 1A2, 1B1) of the cytochrome P450. These enzymes are critical in the bioactivation of 
procarcinogens and are upregulated, inter alia, by ultraviolet-B radiation in the skin [31,32]. 
Based on the above mentioned facts and structural analogy with other CPEs, it was suggested to 
evaluate alaptide as a potential CPE of many anti-inflammatory drugs, antimicrobial chemotherapeutics, 
sex hormones/genital system modulators, or drugs targeting the central/vegetative nervous system 
[4,32,33]. Furthermore, the permeation of micronized (ALA) and nanonized (NALA) alaptide alone through 
the full-thickness pig ear skin from various semi-solid compositions was evaluated and different behaviour 
among both forms was confirmed. Though permeation of NALA through the skin was limited compared 
with ALA [34], NALA was also positively evaluated as a potential modifier of transdermal permeation 
[32,33]. Thus, the aim of this primary rapid study was to evaluate the effect of alaptide in micronized and 
nanonized forms on drug permeation through the skin immediately after application of the drug 
formulation. 
Opatrilova and Jampilek  ADMET & DMPK 2(1) (2014) 56-62 
58  
Mupirocin (pseudomonic acid A, chemically 9-{[(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-{[(2S,3S)-3-
[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl}oxan-2-yl]-3-methylbut-2-enoyl]oxy}nonanoic acid, see 
Fig. 1) is an antibiotic originally isolated from Pseudomonas fluorescens and is structurally unrelated to any 
other antibiotics. It is used topically and primarily effective against Gram-positive bacteria, such as 
Staphylococcus aureus (including methicillin-resistant S. aureus) and beta-hemolytic streptococci, including 
S. pyogenes. It can be used for treatment of furuncles, impetigo, open wounds, etc. Mupirocin is 
bacteriostatic at low concentrations and bactericidal at high concentrations. It has a unique mechanism of 
action, which is selective binding to bacterial isoleucyl-tRNA synthetase, which halts the incorporation of 
isoleucine into bacterial proteins. Following intravenous or oral administration, mupirocin is rapidly 
metabolised. The principal metabolite is monic acid, which has no antibacterial activity; therefore, its 
indication is topical treatment of bacterial skin infections. Mupirocin is mostly formulated as 2% macrogol 
ointment and was originally marketed by GlaxoSmithKline under trade name Bactroban® [35−37]. In a rapid 
in vitro screening, the effect of both forms of alaptide on permeation of mupirocin from Bactroban® Leciva 





















Figure 1. Structures of (S)-alaptide and mupirocin. 
Experimental 
Preparation of alaptide 
Alaptide was synthesised according to the standard process [38]. All reagents were purchased from 
Aldrich and Merck. Alaptide was micronized using a Planetary Ball Mill PM 200, Retsch (Germany). The 
particle size of the used micronized alaptide was measured by a NIKON Optiphot 2 microscope with a VDS 
CCD-1300F digital camera. The particle size distribution (x90) of microcrystalline alaptide was 40 μm. 
The suspension of alaptide (30 g), polyvinylpyrrolidone (30 g) and purified water (240 mL, diluted during 
milling by the addition of 150 mL) was initially mixed for 12 h at ambient temperature and then filtered 
through a mill sieve. The milling procedure was performed using a nanomill NETZSCH (Germany) with glass 
beads (0.3 mm); the rotor speed was 986 rpm; the pump speed was 30 rpm; the temperature in the 
grinding chamber was within 17–20 °C. The rotor speed was increased to 1500 rpm after 6 h of milling. The 
total time of milling was 57.5 h. The content of alaptide in the suspension was 38.76 g/L (determined by RP-
HPLC, see below). The particle size of the prepared nanonized alaptide was measured by Sympatec 
NANOPHOX 0138 P (Germany) and the particle size x90 was 770 nm. 
In vitro transdermal permeation experiments 
Skin samples were obtained from a porcine ear. Full thickness ear skin was cut in fragments and stored 
at −20°C until utilised. Skin samples were slowly thawed (at 4 °C overnight and then at ambient 
temperature) prior to each experiment. The penetration enhancing effect of micronized alaptide (ALA) and 
nanonized alaptide (NALA) was evaluated in vitro, using a vertical Franz diffusion cell (SES – Analytical 
Systems, Germany) with a donor surface area of 0.6359 cm2 and a receptor volume of 5.2 mL. The skin was 
mounted between the donor and receptor compartments of the Franz diffusion cell with the epidermal side 
up. The receptor compartment was filled with phosphate buffered saline (pH 7.4) and maintained at 
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34±0.5 °C using a circulating water bath. The receptor compartment content was continuously stirred using 
a magnetic stirring bar. The skin was kept in contact with the receptor phase for 0.5 h prior to the 
experiment. BACTROBAN® Leciva (2% macrogol ointment produced by Zentiva Prague, Czech Republic) was 
purchased from a pharmacy. The ointment was mixed with ALA or NALA (1% related to drug); ALA or NALA 
dissolved in the ointment and the prepared monophasic compositions were applied to the skin surface as a 
donor sample and the donor compartment of the cell was covered by Parafilm®. BACTROBAN® Leciva was 
used as a control. Samples (0.5 mL) of the receptor phase were withdrawn at four pre-determined time 
intervals (30, 60, 90 and 120 min) and the cell was refilled with an equivalent amount of fresh buffer 
solution. A minimum of five determinations was performed using skin fragments from a minimum of 
two animals for each compound and the data was expressed as means ± SD. The samples were immediately 
analysed by HPLC. 
Analysis of samples was performed using an Agilent 1200 series HPLC system equipped with a diode 
array detection (DAD) system, a quaternary model pump and an automatic injector (Agilent Technologies, 
Germany). Data acquisition was performed using ChemStation chromatography software. A Zorbax Eclipse 
XDB C18 5 μm, 4.6×150 mm (Agilent, USA) chromatographic column was used. The total flow of the column 
was 0.5 mL/min; injection was 10 μL; column temperature was 30 °C; sample temperature was 10 °C. The 
detection wavelength of 210 nm was chosen and the time of analysis was eight minutes. A mixture of 
MeOH (HPLC grade, 75.0%) and H2O (HPLC – Mili-Q Grade, 25.0%) was used as a mobile phase. Mupirocin 
standard was purchased from Sigma-Aldrich. The retention time (tR) of mupirocin was 3.4±0.05 min; the 
limit of detection (LOD) was 9.5 ng/mL; the limit of quantification (LOQ) was 31.7 ng/mL. 
Results and Discussion 
Mupirocin was chosen as a frequently applied antibiotic for topical treatment of bacterial skin infections 
that are often associated with various injuries of the skin, because alaptide itself showed significant 
curative effect on the skin [17,25]. It was supposed that alaptide could influence the time of mupirocin 
retaining on/in the skin and act synergistically with this antibiotic. The rapid in vitro skin permeation 
screening experiments were performed using static Franz diffusion cells [39] in a time limit of two hours 
only. Full-thickness pig ear skin was selected for in vitro evaluation of permeation. This tissue is a suitable in 
vitro model of human skin [40,41], because porcine skin has shown to be histologically and biochemically 
similar to human skin and has previously been used in numerous studies [42]. The permeation of mupirocin 
through full-thickness pig ear skin with and without 1% (w/w related to drug) ALA or NALA was tested using 
BACTROBAN® Leciva, i.e., macrogol ointment as a donor vehicle. The results are listed in Table 1 and 
illustrated in Figure 2. 
Table 1. Cumulative permeated amounts Qt per unit area [μg/cm
2
] of mupirocin (MUP) from BACTROBAN® Leciva 
(macrogol ointment) with and without micronized (ALA) or nanonized (NALA) alaptide as a modifier of transdermal 
permeation achieved in in vitro transdermal permeation experiments using the Franz diffusion cell. Qt are expressed 
as mean ± SD (n = 5 experiments). 
Time [h] 
Cumulative permeated amounts Qt per unit area[µg/cm
2] 
MUP MUP+ALA MUP+NALA 
0.5 301.1±5.8 730.4±6.9 105.8±4.7 
1.0 403.7±6.0 1951.8±8.6 158.3±4.9 
1.5 2861.7±15.0 2337.1±7.0 208.4±7.4 
2.0 4062.7±14.2 3055.2±3.5 248.7±8.8 




Figure 2. In vitro profile of cumulative permeated amounts Qt per unit area [μg/cm
2
] in time of 
mupirocin (MUP) alone and after addition of 1% w/w of micronized (ALA) or nanonized (NALA) alaptide 
from BACTROBAN® Leciva through skin. Qt values are expressed as mean ± SD (n = 5 experiments). 
As the current study represents a preliminary rapid in vitro screening, all the experiments were 
performed only in the time range from 0.5 to 2.0 h. The values obtained from the permeation experiments 
were expressed as the cumulative permeated amount of the drug (Qt [μg]) per unit of skin surface area 
(0.6359 cm2, see Table 1). Due to the short time interval of experiments, steady-state permeation flux and 
lag time could not be calculated; however, this was not the aim of the experiments. The dependences of 
the cumulative permeated amount of the drug per unit of skin surface area in time are shown in Figure 2.  
Based on the results obtained, it can be stated that mupirocin without ALA did not permeate within 1 h 
after application and the permeated amount of mupirocin started to increase rapidly after 1 h; in 1.5 h, the 
permeated concentration of mupirocin was slightly higher than with the addition of ALA. On the other 
hand, in the system containing mupirocin with ALA, the permeated amount of the drug increased 
approximately linearly with time (r = 0.988) during the whole experiment (0-2 h) and in 0.5 and 1h it 
reached approx. 2.5-fold or 5-fold higher values than in the system containing mupirocin without ALA. Thus, 
it can be concluded that the application of ALA to mupirocin in BACTROBAN® Leciva caused a uniform linear 
increase within 1 h when the permeation through the skin with ALA was faster than the permeation 
without ALA. An absolutely different effect was observed with the system containing NALA: the addition of 
1% w/w of NALA to BACTROBAN® Leciva led to a significant decrease of permeation (in fact, the blocking of 
permeation) of mupirocin from BACTROBAN® Leciva through the skin during the experiment (0-2h), 
indicating that both mupirocin and alaptide can act curatively only on the surface of the skin. Although it 
was found that nanoparticles, especially solid lipid nanoparticles also enhanced skin penetration, primarily 
due to an increase in skin hydration caused by the occlusive film formed by these particles on the skin 
surface [43], and that NALA promoted permeation of various anti-inflammatory drugs, analgesics and 
antimicrobial chemotherapeutics through the skin in different studies [32,33], in this case, NALA blocked 
permeation of mupirocin from macrogol. The effect of the lipophilicity of the tested drug, as well as the 
effect of the applied medium/formulation used in this study on behaviour/properties of NALA as a 
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Based on the findings above, it can be assumed that the evaluated pharmaceutical composition of 
mupirocin can be used with success in combination with alaptide. As mentioned above, alaptide 
administered topically/locally supports/induces much faster regeneration and healing of the skin; 
therefore, it can be supposed than alaptide can potentiate the curative effect of mupirocin. The selection of 
the micronized or nanonized form of alaptide can influence the depth and the rate of permeation to the 
skin, i.e., the curative effect. 
Conclusions 
The ability of alaptide in micronized and nanonized forms to modify permeation of mupirocin 
into/through the porcine ear skin was examined using the Franz cell in the rapid preliminary in vitro 
screening. Micronized and nanonized alaptide applied in a concentration of 1% w/w related to the amount 
of mupirocin influenced the permeation/penetration of the drug from the BACTROBAN® Leciva macrogol 
ointment through the skin. According to the calculated cumulative permeated amount of the drug per unit 
of skin surface area, in time, mupirocin with the addition of micronized alaptide, permeated approx. 2.5-
fold or 5-fold more in 0.5 and 1.0 h than without alaptide, i.e., micronized alaptide can significantly 
accelerate the impending effect of mupirocin within 1 h, whereas nanonized alaptide inhibited the 
permeation of mupirocin from the macrogol ointment. This finding, as well as confirmation of the 
mechanism of action of alaptide, will be the aim of our next investigation. Nevertheless, on the basis of the 
preliminary results of the rapid preliminary screening, it can be concluded that alaptide combined with 
mupirocin can influence the depth and the rate of permeation of mupirocin into/through the skin. 
Moreover, alaptide can act as a skin protecting substance due to its skin curative effect. 
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